Market Overview

Evercore ISI's Schoenebaum Breaks Down Celgene-Receptos Merger

Share:

In a new presentation, Evercore ISI analyst Mark Schoenebaum breaks down the recently announced Celgene Corporation (NASDAQ: CELG) buyout of Receptos Inc (NASDAQ: RCPT). The deal is valued at about $7.2 billion, and the $232/share price that Celgene is paying represents about a 12 percent premium to the market value of Receptos at the time the deal was announced.

Major Product

Receptos’ major product is Ozanimod, which is in phase 3 testing for two different indications: multiple sclerosis (MS) and ulcerative colitis (UC).

According to Schoenebaum, Ozanimod is similar to Novartis AG (NYSE: NVS)’s MS drug Gilenya, which currently produces annual sales of about $2.6 billion and is “one of only a few recently approved oral drugs in an MS market historically dominated by injectables.”

However, Schoenebaum points out that subtle differences in Ozanimod’s selectivity could mean that the drug avoids the required warning labels related to slow heart rate and heart block that Gilenya is subject to, which could differentiate Ozanimod from the competition.

When it comes to the UC indication, Schoenebaum once again sees Ozanimod as an active, oral alternative to injectable UC treatments.

Valuation

Evercore is projecting peak Ozanimod sales of about $2.6 billion per year in 2024 and then a slow decline in sales until the drug’s patent cliff in 2033.

These projections fall short of the annual peak projections of $4-$6 billion that Celgene announced.

Celgene sees a negative impact to earnings per share of between -$0.12 and -$0.40 per year for 2015-2017 due to the costs associated with the deal. However, the company raised its 2020 earnings guidance by $0.50 per share.

Threats To The Deal?

Celgene is expecting the deal to close in Q3 of this year. Evercore sees no antitrust issues with the potential deal, and does not expect any meaningful clinical data or FDA activity between now and the expected closing date.

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2019Standpoint ResearchDowngradesBuyHold
Nov 2019BairdDowngradesOutperformNeutral
May 2019BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

 

Related Articles (CELG + RCPT)

View Comments and Join the Discussion!

Posted-In: Evercore ISI Mark SchoenebaumAnalyst Color Biotech M&A Analyst Ratings General

Latest Ratings

StockFirmActionPT
ESTCCanaccord GenuityMaintains150.0
AVAVCanaccord GenuityMaintains98.0
OKTACanaccord GenuityMaintains250.0
SNOWCanaccord GenuityMaintains275.0
RCMSVB LeerinkMaintains26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com